Emerging Infectious Diseases (Mar 2022)

SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020–March 2021

  • Anna R. Giuliano,
  • Shari Pilon-Thomas,
  • Michael J. Schell,
  • Martha Abrahamsen,
  • Jessica Y. Islam,
  • Kimberly Isaacs-Soriano,
  • Kayoko Kennedy,
  • Christopher W. Dukes,
  • Junmin Whiting,
  • Julie Rathwell,
  • Jonathan A. Hensel,
  • Leslie N. Mangual,
  • Ernst Schonbrunn,
  • Melissa Bikowitz,
  • Dylan Grassie,
  • Yan Yang

DOI
https://doi.org/10.3201/eid2803.211495
Journal volume & issue
Vol. 28, no. 3
pp. 556 – 563

Abstract

Read online

Estimating the actual extent of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is challenging because virus test positivity data undercount the actual number and proportion of persons infected. SARS-CoV-2 seroprevalence is a marker of past SARS-CoV-2 infection regardless of presence or severity of symptoms and therefore is a robust biomarker of infection period prevalence. We estimated SARS-CoV-2 seroprevalence among residents of Hillsborough County, Florida, USA, to determine factors independently associated with SARS-CoV-2 antibody status overall and among asymptomatic antibody-positive persons. Among 867 participants, SARS-CoV-2 period prevalence (October 2020–March 2021) was 19.5% (asymptomatic seroprevalence was 8%). Seroprevalence was 2-fold higher than reported SARS-CoV-2 virus test positivity. Factors related to social distancing (e.g., essential worker status, not practicing social distancing, contact with a virus-positive person, and length of contact exposure time) were consistently associated with seroprevalence but did not differ by time since suspected or known infection (6 months).

Keywords